Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.34B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 9.96M
Average 6.11M
Returns on capital
Intellia Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-61.5%
avg -34.5%
ROIC
-57.7%
avg -30.9%
ROA
-49.0%
avg -27.2%
Analysis
ROA is currently the strongest return metric at -49.0% versus its period average of -27.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Erik J. Sontheimer | Founder and Member of Scientific Advisor Board | USD 1.38M | — | — | — |
Luciano Marraffini | Founder and Member of Scientific Advisor Board | USD 1.38M | — | — | — |
Derrick J. Rossi | Founder and Member of Scientific Advisor Board | USD 1.38M | — | — | — |
Rodolphe Barrangou | Founder and Member of Scientific Advisor Board | USD 1.38M | — | — | — |
Jennifer A. Doudna | Founder and Member of Scientific Advisor Board | USD 1.38M | 62 | — | — |
John Leonard | President, Chief Executive Officer & Director | USD 1.26M | 69 | — | — |
Edward J. Dulac | Executive Vice President, Chief Financial Officer and Treasurer | USD 853.71K | 51 | — | — |
James E. Basta | Executive Vice President, General Counsel & Corporate Secretary | USD 732.37K | 60 | — | — |
Birgit Schultes | Executive VP & Chief Scientific Officer | USD 708.86K | 63 | — | — |
Michael Dube | VP & Chief Accounting Officer | USD 478.49K | 48 | — | — |
Rachel E. Haurwitz | Co-Founder | — | 40 | 0 | <0.01% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 11, 2016.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$1.40M
Sells
19
$2.27M
Net Transaction Value
−$868,724.46
Net selling
Most Active
LEONARD JOHN M
7 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 2, 26Nov 2, 2026 | LEONARD JOHN M Direct | Sell | $107.9K$107,910.00 |
| Oct 2, 26Oct 2, 2026 | Dube Michael P Direct | Sell | $23.2K$23,169.52 |
| Aug 21, 26Aug 21, 2026 | LEONARD JOHN M Direct | Sell | $36.2K$36,205.00 |
| Aug 20, 26Aug 20, 2026 | LEONARD JOHN M Direct | Sell | $250.6K$250,614.00 |
| Jul 22, 26Jul 22, 2026 | Dulac Edward J III Direct | Sell | $91.2K$91,248.75 |
| Jul 2, 26Jul 2, 2026 | Dulac Edward J III Direct | Sell | $84.2K$84,186.00 |
| Jul 1, 26Jul 1, 2026 | Dube Michael P Direct | Sell | $44.3K$44,315.98 |
| Mar 2, 26Mar 2, 2026 | BASTA JAMES Direct | Sell | $16.7K$16,687.58 |
| Mar 2, 26Mar 2, 2026 | Clark Eliana Direct | Sell | $8.4K$8,364.46 |
| Jan 5, 26Jan 5, 2026 | LEONARD JOHN M Direct | Sell | $314.5K$314,484.66 |
1–10 of 20
Summary
Insiders reported 1 buys worth $1.40M and 19 sells worth $2.27M over the last 12 months. That adds up to net selling of $868,724.46. LEONARD JOHN M was the most active insider with 7 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +9.1% | +92.2% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +9.1% over three years. Forward estimates point to Revenue at +92.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Intellia Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about NTLA's management, answered from reported figures.
Who manages NTLA?
Intellia Therapeutics, Inc. (NTLA) lists 11 active executives. The top listed executive is John Leonard, President, Chief Executive Officer & Director.
Are NTLA insiders buying or selling?
Recent insider activity shows net buying of $36.48M.
Continue the stock analysis
Jump to another research area for this company.